RTI uses cookies to offer you the best experience online. By clicking “accept” on this website, you opt in and you agree to the use of cookies. If you would like to know more about how RTI uses cookies and how to manage them please view our Privacy Policy here. You can “opt out” or change your mind by visiting: http://optout.aboutads.info/. Click “accept” to agree.

Zach Demkovich

Zach Demkovich

Research Public Health Analyst


MPH, Infectious Diseases and Vaccinology, University of California Berkeley
BS, Biology, Illinois State University


Zach Demkovich does product development and project management for new and innovative technologies with RTI International's Women's Global Health Imperative (WGHI) and in collaboration with our Global Health Technologies (GHT) and Technology Advancement & Commercialization (TAC) groups. He has several years of experience managing preclinical stages and GMP manufacturing of an implantable drug delivery system for HIV prevention. More recently, he’s been gaining experience in the IND submission process for all sorts of investigational products like vaccines, devices, biologics, and cell & gene therapies.

Mr. Demkovich’s notable publications include Predicting pharmacokinetics of a tenofovir alafenamide subcutaneous implant using physiologically based pharmacokinetic modelling and Characterization of a reservoir-style implant for sustained release of tenofovir alafenamide (TAF) for HIV pre-exposure prophylaxis (PrEP).

Get in Touch

To speak to this expert or inquire about RTI services, you can reach us at +1 919 541 6000 or use the contact form below. For media inquiries, please reach out to our Media Relations team at news@rti.org.

Blue background circle graphics